Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections

National Medical Journal of China

Volumn 92, Issue 40, 2012, Pages 2847-2850

  Shi, Yan ^a   Xu, Ying Chun ^a   Liu, Ye ^a   Du, Wei ^a   Rui, Xi ^a   Wang, Yao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Acinetobacter baumannii; Cefoperazone sulbactam; Cross infections; Minocycline

Indexed keywords

CILASTATIN PLUS IMIPENEM; MINOCYCLINE; SULPERAZON;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CLINICAL EFFECTIVENESS; CRITICALLY ILL PATIENT; DRUG EFFICACY; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SITE INFECTION; PROSPECTIVE STUDY; SOFT TISSUE INFECTION; TREATMENT DURATION;

EID: 84872250800     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.40.012     Document Type: Article

References (19)

1. Ouderkirk J P, Nord J A, Turett J S, et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother, 2003, 47: 2659-2662.
2. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol, 2011, 7: 1459-1570.
3. 2007, 7: 34-37.
4. Falagas M E, Karageorgopoulos D E. Pandrug resistance(PDR), extensive drug resistance(XDR), and multidrug resistance(MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis, 2008, 46: 1121-1122.
5. 1987, 2: 126-130.
6. http://www.moh.gov.cn/publicfiles/business/htmlfiles/ mohyzs/s3593/200908/42455.htm.
7. Fishbain J, Peleg A Y. Treatment of Acinetobacter infections. Clin Infect Dis, 2010, 51: 79-84.
8. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23: 332-339.
9. 2010, 10: 325-334.
10. Mendes R E, Bell J M, Turnidge J D, et al.Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. Antimicrob Agents Chemother, 2009, 63: 55-59.
11. Lolans K, Rice T W, Munoz-Price L S, et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother, 2006, 50: 2941-2945.
12. Sopirala M M, Mangino J E, Gebreyes W A, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2010, 54: 4678-4683.
13. 2008, 18: 1431-1433.
14. 2012, 92: 76-83.
15. Lee N Y, Wang C L, Yu W L, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumanniibacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy, 2007, 27: 1506-1511.
16. Hsueh P R, Teng L J, Chen C Y, et al. Emergence of pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis, 2002, 8: 827-832.
17. Sheng W H, Wang J T, Li S Y, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis, 2011, 70: 380-386.
18. Dent L L, Marshall D R, Pratap S, et al. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis, 2010, 10: 196.
19. Tuon F F, Penteado-Filho S R, Amarante D, et al. Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis, 2010, 14: 437-440.